性别和年龄对中轴型脊柱关节炎患者bDMARD疗效的影响:随机对照试验的Meta分析
该Meta分析纳入9项bDMARD随机对照试验共4127例中轴型脊柱关节炎患者,以ASAS40为主要疗效指标。结果显示bDMARD在男女及不同年龄患者中均优于安慰剂,但男性和年轻患者疗效更明显;性别差异在非放射学中轴型脊柱关节炎患者中更突出。
要点
- 与安慰剂相比,男性OR 3.14(95%CI 2.66, 3.70)、女性OR 2.32(95%CI 1.82, 2.82),均显著获益。
- 年轻患者OR 4.00(95%CI 2.50, 6.40)、年长患者OR 2.21(95%CI 1.15, 4.22),均显著获益。
- 性别疗效差异在nr-axSpA患者中更明显(Pheterogeneity=0.03,I2=78.1%)。
核心结论
- bDMARD对中轴型脊柱关节炎患者不论性别或年龄均有效,但男性和年轻患者治疗反应更明显。
- 女性放射学中轴型脊柱关节炎患者疗效优于非放射学患者,而男性两者无相关差异,提示性别差异在非放射学患者中更大。
研究设计与样本
- Meta分析检索PubMed、Scopus和Embase截至2023年8月10日发表的随机对照试验,评估b/tsDMARD在中轴型脊柱关节炎中的疗效。
- 仅1项涉及tsDMARD的研究符合纳入标准但因故被排除进一步分析,最终纳入9项bDMARD研究共4127例患者。
主要发现
- 与安慰剂相比,男性OR 3.14(95%CI 2.66, 3.70)、女性OR 2.32(95%CI 1.82, 2.82),均呈现显著更好的治疗反应。
- 与安慰剂相比,年轻患者OR 4.00(95%CI 2.50, 6.40)、年长患者OR 2.21(95%CI 1.15, 4.22),均呈现显著更好的治疗反应。
- 疗效在男性(OR 1.89,95%CI 1.56, 2.30)和年轻患者(OR 2.07,95%CI 1.42, 3.02)中更明显。
- 亚组分析显示性别疗效差异在非放射学中轴型脊柱关节炎患者中更明显(Pheterogeneity=0.03,I2=78.1%)。
- 男性放射学与非放射学中轴型脊柱关节炎患者对bDMARD反应相似(Pheterogeneity=0.87,I2=0%),而女性放射学患者反应优于非放射学患者(Pheterogeneity=0.005,I2=87.4%)。
关键数值与推荐
- 主要结局指标为国际脊柱关节炎评估协会≥40%改善(ASAS40)的治疗反应。
- 男性与安慰剂比较OR 3.14(95%CI 2.66, 3.70),女性与安慰剂比较OR 2.32(95%CI 1.82, 2.82)。
- 年轻患者与安慰剂比较OR 4.00(95%CI 2.50, 6.40),年长患者与安慰剂比较OR 2.21(95%CI 1.15, 4.22)。
- 男性和年轻患者疗效更明显,OR分别为1.89(95%CI 1.56, 2.30)和2.07(95%CI 1.42, 3.02)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 仅1项涉及tsDMARD的研究符合纳入标准,但被排除进一步分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study the therapeutic variations of biologic and targeted synthetic DMARDs (b/tsDMARDs) between genders and across age stages in axial SpA (axSpA) patients through meta-analysis. METHODS: Randomized controlled trials published by PubMed, Scopus and Embase before 10 August 2023, testing the efficacy of b/tsDMARDs in axSpA, were searched and systematically reviewed. The Assessment of Spondyloarthritis International Society ≥40% improvement (ASAS40) was used as the primary outcome of treatment response. RESULTS: Only one study meet the inclusion criteria related to tsDMARDs, which was excluded from further analysis. Nine studies of bDMARDs, with 4127 patients, were included for the final analysis. When compared with placebo, both males [odds ratio (OR) 3.14 (95% CI 2.66, 3.70)] and females [OR 2.32 (95% CI 1.82, 2.82)] and younger [OR 4.00 (95% CI 2.50, 6.40)] and older [OR 2.21 (95% CI 1.15, 4.22)] patients presented significantly better responses to bDMARDs. Also, the efficacies were more evident in males [OR 1.89 (95% CI 1.56, 2.30)] and younger [OR 2.07 (95% CI 1.42, 3.02)] patients. Subgroup analysis revealed that the gender difference in efficacy was more obvious in non-radiographic axSpA (nr-axSpA) patients (Pheterogeneity = 0.03, I2 = 78.1%). Moreover, males with radiographic axSpA (r-axSpA) and nr-axSpA shared similar responses to bDMARDs (Pheterogeneity = 0.87, I2 = 0%), while females with r-axSpA showed greater response than those with nr-axSpA (Pheterogeneity = 0.005, I2 = 87.4%). CONCLUSIONS: The bDMARDs were efficacious in all axSpA patients regardless of gender or age. However, the treatment responses were more evident in male and younger patients. Also, females with r-axSpA had greater responses than those with nr-axSpA, whereas no relevant difference was observed in males, indicating that the gender difference on efficacy was greater in nr-axSpA patients.
引用
- Xie Y, Liu Y, Wu Q, et al. Effect of gender and age on bDMARD efficacy for axial spondyloarthritis patients: a meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2024. PMID: 38317498. doi:10.1093/rheumatology/keae088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。